TG Therapeutics Inc (NASDAQ:TGTX) Just Reported Decreased Shorts

July 14, 2018 - By Julie Barnes

Investors sentiment decreased to 1.46 in 2018 Q1. Its down 0.54, from 2 in 2017Q4. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported.
Baldwin Brothers Ma reported 17,850 shares. Tower Research Cap Limited Liability (Trc) holds 0% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 2,627 shares. Raymond James Fin Ser Advsrs reported 139,071 shares or 0.01% of all its holdings. Venbio Select Advisor, California-based fund reported 5.23 million shares. Deutsche Savings Bank Ag, a Germany-based fund reported 56,252 shares. Swiss Commercial Bank accumulated 0% or 96,200 shares. State Of Wisconsin Investment Board stated it has 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Hikari Pwr Ltd, a Japan-based fund reported 160,000 shares. Voya Inv stated it has 22,521 shares. Moreover, Fmr Limited Liability Corporation has 0.01% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). 36,592 are held by Virtu Financial Ltd Company. Dupont Cap Management owns 58,421 shares or 0.02% of their US portfolio. Morgan Stanley invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). Ubs Asset Management Americas owns 950,934 shares. Exane Derivatives accumulated 9,834 shares.

Since June 14, 2018, it had 0 insider purchases, and 2 sales for $960,508 activity. KENNEDY WILLIAM JAMES sold $337,205 worth of stock.

The stock of TG Therapeutics Inc (NASDAQ:TGTX) registered a decrease of 11.83% in short interest. TGTX’s total short interest was 10.71M shares in July as published by FINRA. Its down 11.83% from 12.15 million shares, reported previously. With 873,400 shares average volume, it will take short sellers 12 days to cover their TGTX’s short positions. The short interest to TG Therapeutics Inc’s float is 25.28%.

The stock increased 0.37% or $0.05 during the last trading session, reaching $13.45. About 623,196 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since July 14, 2017 and is uptrending. It has outperformed by 2.14% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.04 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin??s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 3 analysts covering TG Therapeutics (NASDAQ:TGTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 6 analyst reports since January 17, 2018 according to SRatingsIntel. The firm has “Buy” rating by FBR Capital given on Wednesday, January 17. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by FBR Capital on Friday, February 2. On Friday, March 9 the stock rating was maintained by FBR Capital with “Buy”. H.C. Wainwright initiated TG Therapeutics, Inc. (NASDAQ:TGTX) on Wednesday, March 21 with “Buy” rating. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Monday, June 4 by FBR Capital. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) earned “Buy” rating by Raymond James on Thursday, April 19.

More news for TG Therapeutics, Inc. (NASDAQ:TGTX) were recently published by:, which released: “Trillium up 13% premarket” on June 21, 2018.‘s article titled: “Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3” and published on June 20, 2018 is yet another important article.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.